Cann Global continued to drive sales throughout the quarter resulting in cash receipts from customers of $333k up 54.6% on the prior corresponding period, but lower than the prior quarter due to shipping delays and therefore delayed payment on contracted sales.
Cann Global Limited
Cann Global Limited's (ASX:CGB) primary focus is to legally grow and cultivate hemp to research and develop medicinal cannabis products to service an increasing demand in the Australian and global markets.
Cann Global Ltd has a 100% shareholding in Medical Cannabis Ltd (MCL) and a management agreement with Medcan Australia Pty Ltd (Medcan) which operate a business cultivating, researching, developing and soon to be distributing medicinal cannabis products in Australia. Our Medical Cannabis division has been a key value driver for the Group.
The Group also retains an interest in its existing Bauxite Projects.
Cann Global Limited (ASX:CGB) is pleased to confirm that the 1 for 4 renounceable entitlement offer announced on 3 July 2020 (Entitlement Offer), closed on Thursday 23 July 2020.
Cann Global Ltd (ASX:CGB) today confirms that its Directors and largest shareholders intend to participate in the rights issues announced on 3 July 2020.
Cann Global Limited's (ASX:CGB) medical Cannabis research division, Medical Cannabis Research Group Pty Ltd (MCRG) entered into a research agreement to research the possibility of the use of cannabis in the treatment of autoimmune disease, specifically multiple sclerosis (MS).
The Board of Cann Global Limited (ASX:CGB) wishes to update our shareholders on the operations of its 55% owned subsidiary Cann Global Asia Pty Ltd, and its activities in Laos PDR.
On 30 April 2020, Cann Global Ltd (ASX:CGB) lodged the Company's quarterly activities and cashflow reports for the period ended 31 March 2020. This amendment includes an updated cashflow report.
In October 2019, Austrade published a report on Australia's food innovators which Cann Global Limited (ASX:CGB), through its subsidiaries T12 and HHC, is very excited to be a part of.
Cann Global Ltd (ASX:CGB) is pleased to advise that the Company has entered into agreements for the refinancing of the convertible notes currently on issue through an assignment and variation arrangement.
The Directors present their report together with the financial statements, on the consolidated entity (referred to hereafter as 'the Group'), consisting of Cann Global Limited ('the Company') and the entities it controlled at the end of or during the half-year ended 31 December 2019.
Cann Global Ltd (ASX:CGB) is pleased to advise that the Company has agreed to place 34 million new fully paid ordinary shares (New Shares) to institutional and sophisticated investors led by New York-based Sea Otter Global.